Premium
The effect of pegylated granulocyte colony‐stimulating factor on collateral function and myocardial ischaemia in chronic coronary artery disease: A randomized controlled trial
Author(s) -
Traupe Tobias,
Stoller Michael,
Gloekler Steffen,
Meier Pascal,
Seiler Christian
Publication year - 2019
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13035
Subject(s) - pegfilgrastim , medicine , cardiology , coronary artery disease , clinical endpoint , placebo , revascularization , ejection fraction , angina , randomized controlled trial , myocardial infarction , heart failure , granulocyte colony stimulating factor , chemotherapy , alternative medicine , pathology , filgrastim
Objective To test the effect of long‐term pegfilgrastim on collateral function and myocardial ischaemia in patients with chronic stable coronary artery disease ( CAD ). Methods This was a prospective clinical trial with randomized 2:1 allocation to pegfilgrastim or placebo for 6 months. The primary study endpoint was collateral flow index ( CFI ) as obtained during a 1‐minute ostial coronary artery balloon occlusion. CFI is the ratio of mean coronary occlusive divided by mean aortic pressure both subtracted by central venous pressure (mm Hg/mm Hg). Secondary endpoints were signs of myocardial ischaemia determined during the same coronary occlusion, that is quantitative intracoronary (i.c.) ECG ST ‐segment shift ( mV ) and the occurrence of angina pectoris. Endpoints were obtained at baseline before and at follow‐up after three subcutaneous study drug injections. Results Collateral flow index in the pegfilgrastim group changed from 0.096 ± 0.076 at baseline to 0.126 ± 0.070 at follow‐up ( P = 0.0039), while in the placebo group CFI changed from 0.157 ± 0.146 to 0.122 ± 0.043, respectively ( P = 0.29); the CFI increment at follow‐up was +0.030 ± 0.075 in the pegfilgrastim group and −0.034 ± 0.148 in the placebo group ( P = 0.0172). In the pegfilgrastim group, i.c. ECG ST ‐segment shift changed from +1.23 ± 1.01 mV at baseline to +0.93 ± 0.97 mV at follow‐up ( P = 0.0049), and in the placebo group, it changed from +0.98 ± 1.02 mV to +1.43 ± 1.09 mV, respectively ( P = 0.05). At follow‐up, the fraction of patients free from angina pectoris during coronary occlusion had increased in the pegfilgrastim but not in the placebo group. Conclusion Pegfilgrastim given over the course of 6 months improves collateral function in chronic stable CAD , which is reflected by reduced myocardial ischaemia during a controlled coronary occlusion.